|Table of Contents|

The expression and clinical significance of plasma lncRNA DLEU2 in thyroid papillary carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 15
Page:
2840-2845
Research Field:
Publishing date:

Info

Title:
The expression and clinical significance of plasma lncRNA DLEU2 in thyroid papillary carcinoma
Author(s):
WANG Anyang1; 2; LI Chaoyou2; HUO Ronghua1; ZHAO Ruhua1; ZHANG He1; LI Min1; 2; XUE Gang1; 2; WU Jingfang1
1.Zhangjiakou Key Laboratory of Thyroid Cancer Precision Diagnosis and Treatment，Hebei Zhangjiakou 075000,China;2.Department of Otolaryngology,Head and Neck Surgery,the First Affiliated Hospital,Hebei North University,Hebei Zhangjiakou 075000,China.
Keywords:
DLEU2; papillary thyroid carcinoma; receiver operating characteristic (ROC) curve; binary Logistic regression
PACS:
R736.1
DOI:
10.3969/j.issn.1672-4992.2023.15.014
Abstract:
Objective:To investigate the relationship between plasma DLEU2 (long non-coding RNA DLEU2) and clinicopathological parameters in papillary thyroid carcinoma (PTC) patients.The risk factors affecting PTC,lymph node metastasis and clinical stage were also discussed.Methods:The biological information of DLEU2 in PTC tissue and normal group was analyzed.DLEU2 levels of 22 pairs of PTC tissue and paracancer tissue and plasma DLEU2 levels of 89 cases of PTC(PTC group) and 36 cases of normal control group (control group) were detected by quantitative real-time PCR.The relationship between the clinicopathological characteristics of PTC patients and the expression of plasma DLEU2 levels was analyzed.The diagnostic efficiency of DLEU2 for PTC was analyzed by receiver operating characteristic (ROC) curve.The factors affecting PTC,lymph node metastasis and clinical staging were analyzed by binary Logistic regression.Results:Biological information showed that DLEU2 expression in 512 cases of PTC tissues was higher than that in 59 cases of normal tissues (P＜0.001).Area under the curve (AUC) was 0.824,95%CI 0.755~0.893.The expression level of DLEU2 in 22 cases of PTC tissues was higher than that those paracancer tissues (P＜0.01).The plasma DLEU2 level in PTC group was higher than that in control group (P＜0.001),and DLEU2 expression was associated with lymph node metastasis,the difference was statistically significant (P＜0.05).ROC curve showed that the cut-off value of DLEU2 was 1.114.The AUC of the diagnosis of PTC was 0.765,95%CI 0.668~0.862,the sensitivity was 61.6%,and the specificity was 80.6%.When the cut-off value of DLEU2 in the PTC group was 1.868,the AUC under the diagnosed lymph node metastasis curve was 0.766,95%CI 0.657~0.876,the sensitivity was 69.6%,and the specificity was 72.7%.Binary Logistic regression showed that the high expression of DLEU2 was a risk factor for PTC (OR=4.178,95%CI 1.287~13.567,P＜0.05),and the TG level of PTC patients was higher than that of normal population (OR=1.002,95%CI 1.000~1.005,P＜0.05).Women had an increased risk of PTC (OR=6.016，95%CI 2.372~15.257，P＜0.01).The level of plasma DLEU2 expression in patients with lymph node metastasis was higher than that the level of plasma DLEU2 expression in patients without lymph node metastasis (OR=3.684,95%CI 1.204~11.266,P＜0.05)，and the TMAb level in patients with lymph node metastasis was higher than that in patients without lymph node metastasis (OR=1.005,95%CI 1.000~1.010,P＜0.05).The level of TG in stage III+IV was higher than that in stage I+II (OR=1.003,95%CI 1.000~1.006,P＜0.05).Conclusion:Plasma DLEU2 is highly expressed in PTC and lymph node metastasis.Thyroid function indexes TMAb and TG are effective predictors of lymph node metastasis and clinical stage of PTC.

References:

［1］SHI L,CONG YZ,WANG ZJ.LncRNA NORAD promotes thyroid carcinoma progression by targeting miR-451［J］.Eur Rev Med Pharmacol Sci,2021，25(20):6187-6195.
［2］郑向前，候秀坤，高明.2017 年第二版 NCCN 甲状腺肿瘤指南解读［J］.中国肿瘤临床，2018,45(1):14-17. ZHENG XQ,HOU XK,GAO M.Interpretation of the 2017 second edition of NCCN thyroid tumor guidelines ［J］.Chinese Oncology,2018,45(1):14-17.
［3］JENDRZEJEWSKI J，THOMAS A，LIYANARACHCHI S，et al.PTCSC3 is involved in papillary thyroid carcinoma development by modulating S100A4 gene expression［J］.J Clin Endocrinol Metab,2015,100(10):1370-1377.
［4］张海超,陈隽,周秦毅,等.经口腔前庭腔镜手术与颈部开放手术治疗甲状腺乳头状癌的临床研究［J］.中国耳鼻咽喉头颈外科,2021,28(08):514-516. ZHANG HC,CHEN J,ZHOU QY,et al.Clinical study on the treatment of papillary thyroid carcinoma by oral vestibular endoscopic surgery and neck open surgery ［J］.Chinese Department of Otolaryngology,Head and Neck Surgery,2021,28(08):514-516.
［5］PENNISI E.ENCODE project writes eulogy for junk DNA［J］.Science,2012,337(6099):1159-1161.
［6］MAY JM,BYLICKY M,CHOPRA S,et al.Long and short non-coding RNA and radiation response:a review［J］.Transl Res,2021，233:162-179.
［7］JIN Y,ZHANG M,DUAN R,et al.Long noncoding RNA FGF14-AS2 inhibits breast cancer metastasis by regulating the miR-370-3p/FGF14 axis［J］.Cell Death Discov,2020，6:103.
［8］XU W,WANG B,CAI Y,et al.DLEU2:A meaningful long noncoding RNA in oncogenesis［J］.Curr Pharm Des,2021，27(20):37-43.
［9］ZHOU Y,SHI H,DU Y,et al.lncRNA DLEU2 modulates cell proliferation and invasion of non-small cell lung cancer by regulating miR-30c-5p/SOX9 axis［J］.Aging(Albany NY),2019,11(18):386-401.
［10］WANG B,HANG J,LI W,et al.Knockdown of LncRNA DLEU2 inhibits cervical cancer progression via targeting miR-128-3p［J］.Onco Targets Ther,2020，13:10173-10184.
［11］ALBI E,CATALDI S,LAZZARINI A,et al.Radiation and thyroid cancer［J］.Int J Mol Sci,2017，18(5)：911-921.
［12］SCHNEIDER DF,CHEN H.New developments in the diagnosis and treatment of thyroid cancer［J］.CA Cancer J Clin,2013，63(6):74-94.
［13］HUARTE M.The emerging role of lncRNAs in cancer［J］.Nat Med,2015，21(11):1253-1261.
［14］MAHMOUDIAN-SANI MR,JALALI A,JAMSHIDI M,et al.Long non-coding RNAs in thyroid cancer:Implications for pathogenesis,diagnosis,and therapy［J］.Oncol Res Treat,2019，42(3):136-142.
［15］LIU Y,ZHANG Y,CHEN C,et al.lncRNA HIF1A-AS2:A potential oncogene in human cancers (review)［J］.Biomed Rep,2021，15(4):85-91.
［16］王海玲，李东霞.LncRNA 与恶性肿瘤侵袭转移研究进展［J］.现代肿瘤医学，2018，26（13）：2114-2117. WANG HL,LI DX.Advances in the research of LncRNA and invasion and metastasis of malignant tumor［J］.Modern Oncology,2018，26（13）：2114-2117.
［17］LI X,XU F,MENG Q,et al.Long noncoding RNA DLEU2 predicts a poor prognosis and enhances malignant properties in laryngeal squamous cell carcinoma through the miR-30c-5p/PIK3CD/Akt axis［J］.Cell Death Dis,2020，11(6):472-486.
［18］GUO Y,BAI M,LIN L,et al.LncRNA DLEU2 aggravates the progression of hepatocellular carcinoma through binding to EZH2［J］.Biomed Pharmacother,2019，1(18):109272.
［19］IRIBARREN C,HASELKORN T,TEKAWA IS,et al.Cohort study of thyroid cancer in a San Francisco Bay area population［J］.Int J Cancer,2001，93(5):745-750.
［20］KIM K,CHO SW,PARK YJ,et al.Association between iodine intake,thyroid function,and papillary thyroid cancer:A case-control study［J］.Endocrinol Metab (Seoul),2021，36(4):790-799.
［21］KIM TH,LEE MY,JIN SM,et al.The association between serum concentration of thyroid hormones and thyroid cancer:a cohort study［J］.Endocr Relat Cancer,2022，29(12):635-644.
［22］何德,温嘉琪,周兴舰,等.分化型甲状腺癌患者血清抗甲状腺球蛋白抗体、甲状腺过氧化物酶抗体及甲状腺球蛋白联合检测的临床意义［J］.当代医学,2021,27(18):63-65. HE D,WEN JQ,ZHOU XJ,et al.Clinical significance of serum anti-thyroglobulin antibody,thyroperoxidase antibody and thyroglobulin combined detection in patients with differentiated thyroid cancer ［J］.Contemporary Medicine,2021,27(18):63-65.
［23］李明明,高海燕,薛静.血浆TSH、Tg在分化型甲状腺癌诊断中的价值探讨［J］.宁夏医学杂志,2021,43(10):949-951. LI MM,GAO HY,XUE J.Value of plasma TSH and Tg in the diagnosis of differentiated thyroid carcinoma ［J］.Ningxia Medical Journal,2021,43(10):949-951.
［24］刘安民,王永梅,李玥.分析甲状腺球蛋白(TG)与分化型甲状腺癌转移灶的相关性及TG的诊断意义［J］.当代医学,2015,21(36):43-44. LIU AM,WANG YM,LI Y.Analysis of the correlation between thyroid globulin (TG) and differentiated thyroid carcinoma metastasis and the diagnostic significance of TG［J］.Contemporary Medicine,2015,21(36):43-44.
［25］石宏丽,李宝发.TGSF和Tg联合检测诊断甲状腺癌的准确性及临床价值研究［J］.中国医学文摘(耳鼻咽喉科学),2022,37(03):94-95. SHI HL,LI BF.Study on the accuracy and clinical value of TGSF and Tg in the diagnosis of thyroid cancer ［J］.Chinese Medicine Abstract (Otolaryngology Science),2022,37(03):94-95.
［26］杨炜,姚丹.结节性甲状腺肿与甲状腺癌并存的诊断与治疗［J］.医学综述,2014,20(7):1312-1314. YANG W,YAO D.Diagnosis and treatment of nodular goiter and thyroid carcinoma ［J］.Medical Review,2014,20(7):1312-1314.
［27］薛燕芬.甲状腺癌患者血清TgAb、TMAb及促甲状腺激素水平的检测意义［J］.现代诊断与治疗,2020,31(17):2786-2787. XUE YF.Detection of serum TgAb,TMAb and thyroid-stimulating hormone levels in patients with thyroid cancer ［J］.Modern Diagnosis and Therapy,2020,31(17):2786-2787.
［28］范群，匡安仁，袁耿彪.血清抗甲状腺球蛋白抗体对分化型甲状腺癌术后复发／转移的诊断价值［J］.中华内分泌代谢杂志，2007,23(6)：494-497． FAN Q,KUANG AR,YUAN GB.The value of serum antithyroglobulin antibody in the diagnosis of postoperative recurrence/metastasis of differentiated thyroid carcinoma ［J］.Chinese Journal of Endocrinology and Metabolism,2007,23(6)：494-497.
［29］黄婷，李卫星，张丽．促甲状腺激素及甲状腺自身抗体与分化型甲状腺癌的关系研究［J］.中国全科医学,2013,16(36)：4258-4261． HUANG T,LI WX,ZHANG L.Study on the relationship between thyroid stimulating hormone and thyroid autoantibody and differentiated thyroid carcinoma［J］.Chinese Journal of General Medicine,2013,16(36)：4258-4261.

Memo

Memo:
河北北方学院2022年度校级重大课题(编号：H2022405034）
Last Update: 2023-06-30